BIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Friday morning. The firm issued a sell rating on the medical technology company’s stock.

BIOLASE Stock Performance

NASDAQ:BIOL opened at $0.15 on Friday. BIOLASE has a 52 week low of $0.13 and a 52 week high of $32.09. The firm has a 50 day moving average of $0.15 and a 200 day moving average of $0.79. The company has a quick ratio of 0.68, a current ratio of 1.26 and a debt-to-equity ratio of 34.06. The stock has a market capitalization of $5.04 million, a price-to-earnings ratio of 0.00 and a beta of 0.67.

BIOLASE (NASDAQ:BIOL) last posted its earnings results on Thursday, March 21st. The medical technology company reported ($1.76) EPS for the quarter. BIOLASE had a negative net margin of 41.97% and a negative return on equity of 555.22%. The firm had revenue of $13.49 million for the quarter.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.